Trending:
-
![]()
June’s top news stories
Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy and safety of S201086/GLPG1972 to treat patients with knee osteoarthritis (OA); and Boehringer Ingelheim Pharmaceuticals and...
-
![]()
May’s top news stories
Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory...
-
![]()
Roundtable: experts share their thoughts on Brexit’s impact on clinical trials
Britain’s impending departure from the EU has raised a host of concerns in the drug development industry. In particular, worries have been voiced over the UK’s possible exclusion from funding...
-
![]()
Pharma Technology Focus – Issue 50
In this issue: Maximising investment by cancer megafunds, positive clinical trials for an antibody to treat lupus, how copper can be used to tackle obesity, whether day and night should...
-
![]()
June’s top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200
Bayer reported positive results from the Phase III RESORCE trial of Stivarga (regorafenib) tablets to treat unresectable hepatocellular carcinoma, and TapImmune initiated its Phase II trial of cancer vaccine TPIV...
-
![]()
May’s top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial
ProMedica and Stemedica planned to begin a human stem cell trial for traumatic brain injury and Cerulean dosed its first patient in a Phase l/ll combination trial of CRLX101 and...
-
![]()
April’s top stories: SynbiCITE’s synthetic biology foundry, Omeros’s phase II clinical trial of OMS721
SynbiCITE opened a commercial synthetic biology foundry at Imperial College London, and Omeros began dosing patients in its new Phase ll clinical trial of OMS721 in corticosteroid-dependent renal diseases. Drugdevelopment-technology.com...
-
![]()
March’s top stories: Tracon’s Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial
Tracon Pharmaceuticals started Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, and ADC Therapeutics began a Phase I trial of its antibody drug conjugate (ADC) ADCT-402....
-
![]()
Pharma Technology Focus – Issue 45
In this issue: Israel’s pharma market, what Brexit would mean for clinical research in the UK, developments in obstetrics, the trouble with inhalable insulin, the FDA’s new support for innovation...
-
![]()
February’s top stories: 60% of trial results not shared, Dilaforette-AGU team-up
Yale School of Medicine researchers revealed about 60% of academic clinical trial results were not shared after completion, and Dilaforette and Arabian Gulf University were to collaborate on a Phase...
